(Q40797057)

23 September 2017

title

Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). (English)

1 reference

23 September 2017

1 reference

Songun I

1

1 reference

23 September 2017

Keizer HJ

2

1 reference

23 September 2017

Hermans J

3

1 reference

23 September 2017

Klementschitsch P

4

1 reference

23 September 2017

de Vries JE

5

1 reference

23 September 2017

Wils JA

6

1 reference

23 September 2017

van der Bijl J

7

1 reference

23 September 2017

van Krieken JH

8

1 reference

23 September 2017

van de Velde CJ

9

1 reference

23 September 2017

language of work or name

1 reference

1 April 1999

1 reference

European Journal of Cancer

23 September 2017

published in

1 reference

23 September 2017

volume

35

1 reference

23 September 2017

issue

4

1 reference

23 September 2017

page(s)

558-562

1 reference

Improving results in the treatment of gastric cancer: an 11-year audit.

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Adenocarcinoma of the stomach: a review of 35 years and 1,710 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Gastric adenocarcinoma. A disease in transition

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Effects of preoperative chemotherapy on gastric adenocarcinomas. A morphologic study of 25 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

How to improve survival after diagnosis of gastric cancer? It's back to the drawing board

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Gastric cancer: a curable disease in Britain

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Early detection of gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Combined intensive chemotherapy and radical surgery for incurable gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Neoadjuvant chemotherapy for high-grade advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900429-8

7 January 2021

10.1016/S0959-8049(98)00429-8

Identifiers

DOI

1 reference

23 September 2017

1 reference